Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”

This editorial reflects on improvements in the cancer drug approval process of the U.S. Food and Drug Administration.

Detalles Bibliográficos
Autor principal: Chabner, Bruce A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507657/
https://www.ncbi.nlm.nih.gov/pubmed/28576859
http://dx.doi.org/10.1634/theoncologist.2017-0202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507657/
https://www.ncbi.nlm.nih.gov/pubmed/28576859
http://dx.doi.org/10.1634/theoncologist.2017-0202

Ejemplares similares